Cargando…
Considerations for Phage Therapy Against Mycobacterium abscessus
There is a global increasing number of Mycobacterium abscessus infections, especially pulmonary infections. Reduced therapeutic options exist against this opportunistic pathogen due to its high intrinsic and acquired levels of antibiotic resistance. Phage therapy is a promising afresh therapy, which...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847891/ https://www.ncbi.nlm.nih.gov/pubmed/33537013 http://dx.doi.org/10.3389/fmicb.2020.609017 |
_version_ | 1783645013888991232 |
---|---|
author | Senhaji-Kacha, Abrar Esteban, Jaime Garcia-Quintanilla, Meritxell |
author_facet | Senhaji-Kacha, Abrar Esteban, Jaime Garcia-Quintanilla, Meritxell |
author_sort | Senhaji-Kacha, Abrar |
collection | PubMed |
description | There is a global increasing number of Mycobacterium abscessus infections, especially pulmonary infections. Reduced therapeutic options exist against this opportunistic pathogen due to its high intrinsic and acquired levels of antibiotic resistance. Phage therapy is a promising afresh therapy, which uses viruses to lyse bacteria responsible for the infection. Bacteriophages have been recently administered under compassionate use to a 15-year-old patient infected with M. abscessus in combination with antibiotics with excellent results. This mini review highlights different recommendations for future phage administrations such as where to look for new phages, the use of cocktail of mycobacteriophages to broaden phage specificity and to tackle resistance and phage insensitivity due to temperate phages present in bacterial genomes, the combined use of phages and antibiotics to obtain a synergistic effect, the liposomal administration to reach a prolonged effect, intracellular delivery and protection against neutralizing antibodies, and the convenience of using this strategy in patients suffering from cystic fibrosis (CF) since phages are believed to promote immunomodulatory actions and eliminate biofilms. |
format | Online Article Text |
id | pubmed-7847891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78478912021-02-02 Considerations for Phage Therapy Against Mycobacterium abscessus Senhaji-Kacha, Abrar Esteban, Jaime Garcia-Quintanilla, Meritxell Front Microbiol Microbiology There is a global increasing number of Mycobacterium abscessus infections, especially pulmonary infections. Reduced therapeutic options exist against this opportunistic pathogen due to its high intrinsic and acquired levels of antibiotic resistance. Phage therapy is a promising afresh therapy, which uses viruses to lyse bacteria responsible for the infection. Bacteriophages have been recently administered under compassionate use to a 15-year-old patient infected with M. abscessus in combination with antibiotics with excellent results. This mini review highlights different recommendations for future phage administrations such as where to look for new phages, the use of cocktail of mycobacteriophages to broaden phage specificity and to tackle resistance and phage insensitivity due to temperate phages present in bacterial genomes, the combined use of phages and antibiotics to obtain a synergistic effect, the liposomal administration to reach a prolonged effect, intracellular delivery and protection against neutralizing antibodies, and the convenience of using this strategy in patients suffering from cystic fibrosis (CF) since phages are believed to promote immunomodulatory actions and eliminate biofilms. Frontiers Media S.A. 2021-01-18 /pmc/articles/PMC7847891/ /pubmed/33537013 http://dx.doi.org/10.3389/fmicb.2020.609017 Text en Copyright © 2021 Senhaji-Kacha, Esteban and Garcia-Quintanilla. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Senhaji-Kacha, Abrar Esteban, Jaime Garcia-Quintanilla, Meritxell Considerations for Phage Therapy Against Mycobacterium abscessus |
title | Considerations for Phage Therapy Against Mycobacterium abscessus |
title_full | Considerations for Phage Therapy Against Mycobacterium abscessus |
title_fullStr | Considerations for Phage Therapy Against Mycobacterium abscessus |
title_full_unstemmed | Considerations for Phage Therapy Against Mycobacterium abscessus |
title_short | Considerations for Phage Therapy Against Mycobacterium abscessus |
title_sort | considerations for phage therapy against mycobacterium abscessus |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847891/ https://www.ncbi.nlm.nih.gov/pubmed/33537013 http://dx.doi.org/10.3389/fmicb.2020.609017 |
work_keys_str_mv | AT senhajikachaabrar considerationsforphagetherapyagainstmycobacteriumabscessus AT estebanjaime considerationsforphagetherapyagainstmycobacteriumabscessus AT garciaquintanillameritxell considerationsforphagetherapyagainstmycobacteriumabscessus |